You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
Biological Activity for Nemonapride
Nemonapride is a highly potent dopamine D2-like receptor antagonist; selective over D1-like receptors (Ki values are 0.1 and 740 nM for D2-like and D1-like receptors respectively). Also potent 5-HT1A receptor agonist (IC50 = 34 nM) and has affinity for sigma receptors.
Compound Libraries for Nemonapride
Technical Data for Nemonapride
|Storage||Store at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solubility Data for Nemonapride
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions for Nemonapride
The following data is based on the product molecular weight 387.91. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|0.25 mM||10.31 mL||51.56 mL||103.12 mL|
|1.25 mM||2.06 mL||10.31 mL||20.62 mL|
|2.5 mM||1.03 mL||5.16 mL||10.31 mL|
|12.5 mM||0.21 mL||1.03 mL||2.06 mL|
References for Nemonapride
References are publications that support the biological activity of the product.
Assie et al (1997) 5-HT1A receptor agonist properties of the antipsychotic, nemonapride: comparison with bromerguride and cloz. Eur.J.Pharmacol. 334 141 PMID: 9369342
Terai et al (1983) Selective binding of YM-09151-2, a new potent neuroleptic, to D2-DArgic receptors. Jpn.J.Pharmacol. 33 749 PMID: 6138453
Ujike et al (1996) [3H]YM-09151-2 (nemonapride), a potent radioligand for both sigma1 and sigma2 receptor subtypes. Neuroreport 7 1057 PMID: 8804051
If you know of a relevant reference for Nemonapride, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: Nemonapride, Nemonapride supplier, 5-HT1A, agonists, potent, D2-like, dopamine, antagonists, Serotonin, Receptors, Non-Selective, dopaminergic, YM09151, YM09151-2, YM, 09151, 09151-2, Non-selective, Dopamine, 1746, Tocris Bioscience
1 Citation for Nemonapride
Citations are publications that use Tocris products. Selected citations for Nemonapride include:
Gadgaard & Jensen (2020) Functional characterization of 5-HT1A and 5-HT1B serotonin receptor signaling through G-protein-activated inwardly rectifying K+ channels in a fluorescence-based membrane potential assay Biochem Pharmacol 175 PMID: 32088264
Do you know of a great paper that uses Nemonapride from Tocris? Please let us know.
Reviews for Nemonapride
There are currently no reviews for this product. Be the first to review Nemonapride and earn rewards!
Have you used Nemonapride?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Dopamine Receptors Scientific Review
Written by Phillip Strange and revised by Kim Neve in 2013, this review summarizes the history of the dopamine receptors and provides an overview of individual receptor subtype properties, their distribution and identifies ligands which act at each receptor subtype. Compounds available from Tocris are listed.
Parkinson's Disease Poster
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.